Company DiaMedica Inc. Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
Jul. 01 | DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding | CI |
Jun. 27 | Transcript : DiaMedica Therapeutics Inc. - Special Call |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Chief Tech/Sci/R&D Officer | 62 | Jan. 21 | |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
Paul Papi
IRO | Public Communications Contact | - | 16-11-30 |
Corporate Officer/Principal | - | - | |
Dominic Cundari
PRN | Corporate Officer/Principal | - | 22-01-31 |
David Wambeke
PRN | Corporate Officer/Principal | - | 23-04-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
Michael Giuffre
BRD | Director/Board Member | 68 | 10-08-09 |
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Richard Pilnik
CHM | Chairman | 67 | 09-04-30 |
Charles Semba
BRD | Director/Board Member | 64 | 21-07-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,963,916 | 21,123,153 ( 55.64 %) | 0 | 55.64 % |
Company contact information
DiaMedica Therapeutics, Inc.
301 Carlson Parkway Suite 210
55305, Minneapolis
+
http://www.diamedica.comSector
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock
- Company DiaMedica Inc.